| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Entrada Therapeutics, Inc. (TRDA) has 7 insiders with recent SEC Form 4 filings, including 12 buys and 26 sells. TRDA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 4.68M | $33.03M | - | |
| 10% | 2.85M | $20.10M | -116,474 | |
| 10% | 2.85M | $20.10M | -116,474 | |
| CEO | 526.0K | $3.71M | - | |
| Pres | 216.3K | $1.53M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2025 | Baker Bros. Advisors LP59 | 10% Owner | Buy | 178,044 | $7.60 | $1,352,586.68 | +0.6% | +35.1% | - | |
| Jul 9, 2025 | 5am Ventures V, L.P.62 | 10% Owner | Sell | 27,000 | $7.50 | $202,554.00 | -0.6% | -22.7% | - | |
| Jul 9, 2025 | Parmar Kush62 | Director, 10% Owner | Sell | 27,000 | $7.50 | $202,554.00 | -0.6% | -22.7% | - | |
| Jul 1, 2025 | Parmar Kush62 | - | Sell | 125,000 | $6.93 | $866,632.50 | -1.0% | -17.9% | +6.8% | |
| Jul 1, 2025 | 5am Ventures V, L.P.62 | - | Sell | 125,000 | $6.93 | $866,632.50 | -1.0% | -17.9% | +6.8% | |
| Mar 17, 2025 | Wentworth Kory James61 | Chief Financial Officer | Sell | 1,784 | $10.67 | $19,035.28 | -1.6% | -31.5% | +16.5% | |
| Dec 11, 2024 | Mpm Bioventures 2014, L.P.67 | 10% Owner | Sell | 44,722 | $20.51 | $917,110.96 | -0.5% | -46.5% | -45.7% | |
| Dec 11, 2024 | Mpm Bioventures 2018, L.P.54 | 10% Owner | Sell | 44,722 | $20.51 | $917,110.96 | -0.5% | -46.5% | -45.7% | |
| Dec 3, 2024 | Sethuraman Natarajan83 | President, Research &Develop. | Sell | 15,891 | $20.18 | $320,619.70 | -3.3% | -43.8% | -50.1% | |
| Dec 2, 2024 | Wentworth Kory James61 | Chief Financial Officer | Sale+OE | 6,000 | $19.99 | $119,948.30 | -3.9% | -44.2% | -51.5% |